# A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients

> **NCT01092832** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 23 (actual)

## Conditions studied

- Candidiasis

## Interventions

- **DRUG:** voriconazole

## Key facts

- **NCT ID:** NCT01092832
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-10
- **Primary completion:** 2013-05
- **Final completion:** 2013-06
- **Target enrollment:** 23 (ACTUAL)
- **Why stopped:** This protocol terminated prematurely on July 8, 2013 due to slow enrollment, not because of any safety issues or concerns.
- **Last updated:** 2016-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01092832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01092832, "A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01092832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*